Michael Callaghan
Pediatric Hematology-Oncology · Detroit, MINPI 1285843672
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Genentech USA, Inc. at 32.6% of the total. Reporting peaked in 2019 at $196,717 and has fallen 96.1% since, to $7,744 in 2024. Among pediatric hematology-oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $1473.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$122K
- F. Hoffmann-la Roche AG$76K
- Hoffmann-la Roche Limited$30K
- Biomarin Pharmaceutical Inc.$30K
- Novo Nordisk$23K
- Shire North American Group Inc$19K
- plus $76K from 12 others
Across 105 payments — averaging $3034.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$220K
- Genentech, Inc.$35K
- F. Hoffmann-la Roche AG$32K
- Global Blood Therapeutics, Inc.$26K
- HEMA Biologics, LLC$4K
- Pfizer$1K
What the payments were for
- Consulting fees$143,86238%
- Speaking & faculty fees$134,88036%
- Grants$16,9745%
- Travel & lodging$70,33919%
- Food & beverage$6,9392%
- Education$1,1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 91 | $121,913 |
| F. Hoffmann-la Roche AG | 35 | $75,504 |
| Hoffmann-la Roche Limited | 10 | $30,021 |
| Biomarin Pharmaceutical Inc. | 27 | $29,535 |
| Novo Nordisk | 22 | $22,866 |
| Shire North American Group Inc | 19 | $18,627 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $15,615 |
| Global Blood Therapeutics, Inc. | 11 | $15,448 |
| Roche Products Limited | 4 | $14,034 |
| Spark Therapeutics, Inc. | 5 | $10,371 |
| Pfizer | 10 | $8,634 |
| Bioverativ Therapeutics Inc. | 1 | $4,314 |
| Sanofi | 1 | $4,010 |
| Chiesi USA, Inc. | 1 | $2,610 |
| Eagle Pharmaceuticals, Inc. | 1 | $400 |
| Kedrion Biopharma Inc. | 2 | $124 |
| Emmaus Medical, Inc. | 3 | $110 |
| Novartis | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$184,634
- Non-Covered Product$31,355
- OXBRYTA$12,001
- ADVATE$11,952
- BENEFIX$4,917
- REBINYN$3,718
- NovoSeven RT$1,360
- ADYNOVATE$121
- FEIBA$121
- OBIZUR$121
How this compares
$374,156 in reported general payments places this provider in the 95th percentile of 84 pediatric hematology-oncology providers in Michigan.
See all pediatric hematology-oncology providers in Michigan →
Other pediatric hematology-oncology in Detroit
- Ahmar ZaidiDetroit$119K
- Katherine ReglingDetroit$81K
- Alexander GlarosDetroit$64K
- Brian BermanDetroit$28K
- Roland ChuDetroit$12K
- Alissa MartinDetroit$6K
- Edward PeresDetroit$5K
- Mark ShamounDetroit$3K
- Meret HenryDetroit$3K
- Gianna ValentiDetroit$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.